SIGNABLOK, INC.
Doing business as SIGNABLOK INC
- WORCESTER, MA 01604-1000
- signablok.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
SIGNABLOK, INC. has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About SIGNABLOK, INC.
- Headquarters
- WORCESTER, MA 01604-1000
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIJM5UN38YM1H7
- CAGE5Z7P9
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 17 awards
- Total awarded
- $7,696,076
- By phase
- SBIR Phase I: 14
- SBIR Phase II: 3
- By agency
- Department of Health and Human Services: 16
- Department of Defense: 1
- Active projects
- 1 project
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 1 project
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 2
- 2023: 2
- 2020: 3
- 2019: 1
- 2018: 2
- 2017: 1
- 2016: 1
- 2015: 1
- 2014: 2
- 2012: 2
Awards (most recent first)
TREM-1 therapy for the treatment of empyema
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $457,954
Sep 15, 2025 – Aug 30, 2026
Solicitation PA24-245 (2024) · Topic NHLBI
First-in-class TREM-1 inhibitors for neovascular retinal diseases
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $830,491
Feb 1, 2025 – Jan 31, 2027
- Active
- Ends Jan 2027
Solicitation PA21-259 (2021) · Topic 100
First-in-class TREM-1 inhibitors for neovascular retinal diseases
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $278,127
Sep 30, 2023 – Sep 29, 2024
Solicitation PA21-259 (2021) · Topic 100
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $272,741
Aug 1, 2023 – Apr 30, 2024
Solicitation PA22-176 (2022) · Topic NHLBI
First-in-class TREM-1 Radioprotector to Prevent the Effects of Acute Radiation Syndrome
SBIR Phase I · Department of Defense (Defense Health Agency) · 2020 · $220,006
Sep 24, 2020 – Apr 23, 2021
Solicitation 20.1 (2020) · Topic DHA201-002
TREM-1 inhibitor for the treatment of scleroderma
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $249,601
Sep 10, 2020 – Aug 31, 2021
Solicitation PA19-272 (2019) · Topic NIAMS
TREM-1 therapy for rheumatoid arthritis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $258,603
Sep 9, 2020 – Aug 31, 2021
Solicitation PA19-272 (2019) · Topic NIAMS
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $1,997,806
Sep 25, 2019 – Aug 31, 2021
Solicitation PA18-574 (2018) · Topic 102
Novel TREM-1 targeting therapies for sepsis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $224,996
Sep 1, 2018 – May 31, 2020
Solicitation PA17-302 (2017) · Topic 300
Development of first-in-class TREM-1 inhibitors for neovascular retinal diseases
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $226,223
Jun 1, 2018 – May 31, 2020
Solicitation PA17-302 (2017) · Topic NEI
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $226,756
Sep 21, 2017 – Aug 31, 2019
Solicitation PA16-302 (2016) · Topic 102
Treatment of alcoholic liver disease with novel targeted inhibitors
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $223,443
Sep 5, 2016 – May 31, 2018
Solicitation PA14-071 (2014) · Topic 350
Development of novel targeted agents in pancreatic cancer
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $219,937
Aug 18, 2015 – Dec 31, 2016
Solicitation PA14-071 (2015) · Topic 100
Multifunctional nanoformulations for diagnostic imaging of atherosclerosis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2014 · $1,342,812
Jul 18, 2014 – Apr 30, 2017
Solicitation PA13-234 (2014) · Topic NHLBI
Novel mechanism-based targeted approach to rheumatoid arthritis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $223,013
Solicitation PA14-071 (2014) · Topic NIAMS · Research partner: Stub
Development of novel targeted agents in lung cancer
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $221,738
Solicitation PA11-096 (2012) · Topic NCI · Research partner: Stub
Multifunctional nanoformulations for diagnostic imaging of atherosclerosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $221,829
Solicitation PA11-096 (2012) · Topic NHLBI · Research partner: Stub
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
- 541713Research and Development in NanotechnologySmall business under this code’s size standard
- 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov reports this entity as small under 2 of 3 NAICS codes. Size is determined per code (SBA size standards).
Product & service codes (PSC)
- AN41HEALTH R&D SERVICES; HEALTH CARE - OTHER; BASIC RESEARCH
- AN43HEALTH R&D SERVICES; HEALTH CARE - OTHER; EXPERIMENTAL DEVELOPMENT
PSC names from the Acquisition.gov PSC Manual (opens in a new tab) (April 2025 edition), checked Nov 12, 2026.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with SIGNABLOK, INC.?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.